Quantcast
Home > Quotes > AMPH
AMPH

Amphastar Pharmaceuticals, Inc. Common Stock (AMPH) Quote & Summary Data

$20.94
*  
0.17
0.81%
Get AMPH Alerts
*Delayed - data as of Dec. 13, 2018 13:53 ET  -  Find a broker to begin trading AMPH now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AMPH Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 20.93 / $ 20.95
1 Year Target
24
Today's High / Low
$ 21.30 / $ 20.885
Share Volume
81,202
50 Day Avg. Daily Volume
229,999
Previous Close
$ 21.11
52 Week High / Low
$ 22.74 / $ 14.40
Market Cap
965,301,899
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.14
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.07

Intraday Chart

Shares Traded

Share Volume:
81,202
50 Day Avg. Daily Volume:
229,999

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.14

Trading Range

The current last sale of $20.94 is 45.42% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 21.30 $ 22.74
 Low: $ 20.885 $ 14.40

ETFs with AMPH as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
2.95% Invesco Dynamic Pharmaceuticals ETF (PJP) -2.60 (-3.72%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API, products. We currently manufacture and sell over 20 products. Additionally, we are currently developing a portfolio of 15 generic abbreviated new drug applications, or ANDAs, three generic biosimilar product candidates and six proprietary product candidates. For the years ended December 31, 2017, 2016, and 2015, we recorded net revenues of $240.2 million, $255.2 million, and $251.5 million, respectively. We recorded net income of $4.5 million and $10.5 million for the years ended December 31, 2017 and 2016, respectively, and recorded a net loss of $2.8 million for the year ended December 31, 2015.  ... More ...  


Risk Grade

Where does AMPH fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 21.20
Open Date:
Dec. 13, 2018
Close Price:
$ 21.11
Close Date:
Dec. 12, 2018

Consensus Recommendation

Analyst Info